Dose finding study on panipenem/betamipron in bacterial pneumonia

Kohei Hara, Shigeru Kohno, Hironobu Koga, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Kazuo Takebe, Toyoichi Tamura, Mitsuo Masuda, Masashi Tamura, Kazuki Konishi, Takashi Mohri, Akira Watanabe, Masakichi Motomiya, Izumi Hayashi, Saburo Izumi, Kaoru Shimada, Takashi Inamatsu, Jingoro Shimada, Kohya ShibaMasaki Yoshida, Osamu Sakai, Atsushi Saito, Hiroyuki Kobayashi, Shin Kawai, Shigeki Odagiri, Kaneo Suzuki, Fumio Matsumoto, Takeo Imai, Tosiyuki Yamamoto, Kanzo Suzuki, Satoru Adachi, Toru Matsuura, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Fumio Miki, Rinzo Soejima, Masaru Sumi, Jiro Hino, Michio Yamakido, Kenji Hasegawa, Mikio Oosaki, Keizo Matsumoto, Atsushi Takahashi, Masaru Nasu, Yoichiro Goto, Atsushi Saito, Yositeru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Jun Inatome, Mitsuyoshi Nakashima, Yasuyuki Hayashi, Toyoko Oguri

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)

    Abstract

    In order to find an optimal dose of panipenem/betamipron (PAPM/BP), a carbapenem antibiotic, for the treatment of bacterial pneumoia, a comparative study was performed using imipenem/cilastatin sodium (IPM/CS) as a control drug, and the following results were obtained: PAPM/BP at 1.0 (group L) or 1.5 (group H) g/day in 2-divided doses and IPM/CS at 1.0 g/day (group IPM) in 2-divided doses were systemically administered for 14 days. 1) Clinical effects: Excellent efficacy and efficacy rates were respectively evaluated by the committee to be 6.7% (2/30) and 80% (24/30) in group L, 0% (0/24) and 87.5% (21/24) in group H, and 0% (0/19) and 94.7% (18/19) in group IPM, showing no significant differences among the 3 groups. 2) Bacteriological effects: Bacterial eradication rates were determined to be 100% (14/14) in group L, 77.8% (7/9) in group H, and 100% (8/8) in group IPM. 3) Side effects: Incidences were found to be 0% (0/36) in group L, 6.1% (2/33) in group H, and 6.7% (2/30) in group IPM. None of these side effects were serious. 4) Abnormal laboratory test findings: Incidences were calculated to be 28.6% (10/35) in group L, 36.7% (11/30) in group H, and 21.4% (6/28) in group IPM. These abnormal findings were not serious, but the incidence in group H exceeded 30%. 5) Usefulness: Usefulness rates evaluated by the committee were 76.7% (23/30) in group L, 80.0% (20/25) in group H, and 85.0% (17/20) in group IPM, showing no significant differences among the 3 groups. From these results, 0.5 g×2/day was thought to be an optimal clinical dose of PAPM/BP for the treatment of bacterial pneumonia.

    Original languageEnglish
    Pages (from-to)348-366
    Number of pages19
    JournalChemotherapy
    Volume40
    Issue number3
    DOIs
    Publication statusPublished - 1992 Mar

    Keywords

    • Bacterial pneumonia
    • Dose-finding study
    • panipenem/betamipron

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Dose finding study on panipenem/betamipron in bacterial pneumonia'. Together they form a unique fingerprint.

    Cite this